Legal & General Group PLC Zynerba Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$3.31 - $6.54 $13,220 - $26,120	-3,994 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$2.9 - $6.16 $3,288 - $6,985	-1,134 Reduced 22.11%	3,994 $15,000
Q4 2019 Feb 13, 2020	BUY	$5.61 - $8.57 $5,458 - $8,338	973 Added 23.42%	5,128 $31,000
Q3 2019 Nov 13, 2019	BUY	$7.56 - $15.44 $5,254 - $10,730	695 Added 20.09%	4,155 $31,000
Q2 2019 Aug 14, 2019	BUY	$5.4 - $15.5 $18,684 - $53,630	3,460 New	3,460 $47,000

Q2 2018 Aug 10, 2018	SELL	$7.98 - $12.39 $19,439 - $30,182	-2,436 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$8.69 - $14.59 $21,168 - $35,541	2,436	2,436 $30,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.